REACH InsightsDanielle Drayton2026-05-20T17:50:49+00:00

REACH Insights

Why IgA Nephropathy Is Entering a New Commercial Phase

February 10th, 2026|

MARKETVUE® REPORT: More than half of STXBP1 Encephalopathy patients experience refractory seizures with currently available antiepileptics

January 25th, 2024|

MARKETVUE® REPORT: Over 80% of Tardive Dyskinesia patients are currently prescribed Austedo or Ingrezza, according to U.S. Neurologists

January 17th, 2024|

MARKETVUE® REPORT: Surgery remains the only option for the ~50% of LQTS patients refractory or intolerant to beta blockers

November 9th, 2023|

Why IgA Nephropathy Is Entering a New Commercial Phase

Danielle Drayton2026-02-10T14:54:35+00:00February 10th, 2026|

MARKETVUE® REPORT: More than half of STXBP1 Encephalopathy patients experience refractory seizures with currently available antiepileptics

Amanda Theocles2024-01-25T16:21:25+00:00January 25th, 2024|

MARKETVUE® REPORT: Over 80% of Tardive Dyskinesia patients are currently prescribed Austedo or Ingrezza, according to U.S. Neurologists

Amanda Theocles2024-01-17T16:25:24+00:00January 17th, 2024|

MARKETVUE® REPORT: Surgery remains the only option for the ~50% of LQTS patients refractory or intolerant to beta blockers

Amanda Theocles2023-11-09T17:40:04+00:00November 9th, 2023|

Previous 234 Next